Cargando…

Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice

Background: The most effective symptomatic treatment in Parkinson’s disease (PD) is levodopa in standard doses. However, as the disease progresses, there may be a need for a more personalized approach and fine tuning, in accordance with the patients’ needs. This study aims to evaluate the individual...

Descripción completa

Detalles Bibliográficos
Autores principales: Grétarsdóttir, Helga María, Widman, Erik, Johansson, Anders, Nyholm, Dag
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400411/
https://www.ncbi.nlm.nih.gov/pubmed/34442364
http://dx.doi.org/10.3390/jpm11080720
_version_ 1783745308666101760
author Grétarsdóttir, Helga María
Widman, Erik
Johansson, Anders
Nyholm, Dag
author_facet Grétarsdóttir, Helga María
Widman, Erik
Johansson, Anders
Nyholm, Dag
author_sort Grétarsdóttir, Helga María
collection PubMed
description Background: The most effective symptomatic treatment in Parkinson’s disease (PD) is levodopa in standard doses. However, as the disease progresses, there may be a need for a more personalized approach and fine tuning, in accordance with the patients’ needs. This study aims to evaluate the individual experience of levodopa/carbidopa 5/1.25 mg microtablets (LC-5) in clinical practice with respect to efficacy, tolerability, and usability. The method used was as follows: patients answered a questionnaire concerning the effect and usability of LC-5, and their medical records were reviewed. Regarding results, thirty-five survey responses were obtained, and 29 patients’ medical records were reviewed. The LC-5 dose dispenser usability was generally rated positively and facilitated medication adherence. The majority (85%) of patients reported symptom improvement while using LC-5, compared with previous standard treatments. These results suggest that LC-5 therapy is generally well-tolerated, with favorable patient-reported efficacy and user friendliness, as well as the possibility for an individualized, fine-tuned PD treatment. Further studies with a prospective design and larger study population are needed to confirm the results.
format Online
Article
Text
id pubmed-8400411
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84004112021-08-29 Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice Grétarsdóttir, Helga María Widman, Erik Johansson, Anders Nyholm, Dag J Pers Med Article Background: The most effective symptomatic treatment in Parkinson’s disease (PD) is levodopa in standard doses. However, as the disease progresses, there may be a need for a more personalized approach and fine tuning, in accordance with the patients’ needs. This study aims to evaluate the individual experience of levodopa/carbidopa 5/1.25 mg microtablets (LC-5) in clinical practice with respect to efficacy, tolerability, and usability. The method used was as follows: patients answered a questionnaire concerning the effect and usability of LC-5, and their medical records were reviewed. Regarding results, thirty-five survey responses were obtained, and 29 patients’ medical records were reviewed. The LC-5 dose dispenser usability was generally rated positively and facilitated medication adherence. The majority (85%) of patients reported symptom improvement while using LC-5, compared with previous standard treatments. These results suggest that LC-5 therapy is generally well-tolerated, with favorable patient-reported efficacy and user friendliness, as well as the possibility for an individualized, fine-tuned PD treatment. Further studies with a prospective design and larger study population are needed to confirm the results. MDPI 2021-07-26 /pmc/articles/PMC8400411/ /pubmed/34442364 http://dx.doi.org/10.3390/jpm11080720 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Grétarsdóttir, Helga María
Widman, Erik
Johansson, Anders
Nyholm, Dag
Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
title Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
title_full Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
title_fullStr Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
title_full_unstemmed Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
title_short Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
title_sort personalized medicine approach in treating parkinson’s disease, using oral administration of levodopa/carbidopa microtablets in clinical practice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400411/
https://www.ncbi.nlm.nih.gov/pubmed/34442364
http://dx.doi.org/10.3390/jpm11080720
work_keys_str_mv AT gretarsdottirhelgamaria personalizedmedicineapproachintreatingparkinsonsdiseaseusingoraladministrationoflevodopacarbidopamicrotabletsinclinicalpractice
AT widmanerik personalizedmedicineapproachintreatingparkinsonsdiseaseusingoraladministrationoflevodopacarbidopamicrotabletsinclinicalpractice
AT johanssonanders personalizedmedicineapproachintreatingparkinsonsdiseaseusingoraladministrationoflevodopacarbidopamicrotabletsinclinicalpractice
AT nyholmdag personalizedmedicineapproachintreatingparkinsonsdiseaseusingoraladministrationoflevodopacarbidopamicrotabletsinclinicalpractice